Tesamorelin Research
Falutz 2010 — JCEM Pooled Phase 3 Analysis
Journal of Clinical Endocrinology and Metabolism
Falutz J, et al.
Summary
Pooled VAT treatment effect = -15.4% at 26 wk
Study Details
Study Design
Pooled analysis of two Phase 3 RCTs
Indication
HIV-associated lipohypertrophy
Intervention
2 mg SC daily
Species
Human
Sample Size
806 subjects
Risk of Bias Assessment
Industry-funded
Tags
SourcePooled AnalysisPhase3Tier 1